Tag: Biosimilars
OneSource Specialty Pharma, Formycon enter strategic manufacturing partnership for biosimilars
OneSource Specialty Pharma has entered into a strategic manufacturing partnership with Germany-based biosimilar developer Formycon AG to support the manufacture of biosimilar medicines for global markets.
Emcure to acquire remaining 12.05% stake in Gennova
The transaction will make Gennova a wholly owned subsidiary of Emcure as the biopharma business shifts its focus towards biologics, biosimilars and related therapeutic...
SteinCares and Shilpa Biologicals strike into licensing agreement to expand access...
Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars across Latin America
“Biologics and biosimilars represent Veeda’s second-highest strategic priority after clinical trials”
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans
Fitch Ratings revises Biocon Biologics outlook from ‘stable’ to ‘positive’
Fitch said the ‘Positive’ outlook of the Company’s credit rating reflects its expectation of a sustained reduction in Biocon Limited's financial leverage
Samsung Bioepis reaches settlement agreement for Eylea (Aflibercept) biosimilar in Europe...
This agreement enables Samsung Bioepis to launch SB15 in the United Kingdom (UK) from January 2026, in the rest of Europe from April 2026
Budget 2026: OPPI calls ‘Biopharma Shakti’ India’s leap toward global leadership
The Budget’s focused push on biologics and biosimilars, backed by a dedicated biopharma innovation network, was described by Matai as positioning India strongly for the next wave of complex, high-value therapies
Biocon unifies with Biocon Biologics to establish a single global biopharma...
This integration will enable Biocon to leverage the combined strengths of its biosimilars and generics operations across more than 120 countries
Biocon Biologics secures market entry date for Denosumab biosimilars in...
The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025
Indian pharma industry welcomes FDA move to accelerate biosimilar development
The FDA released a new draft guidance proposing major changes to simplify biosimilarity studies and reduce unnecessary clinical testing